MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea, January 09, 2025--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company ...

MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea, January 09, 2025--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5 ...

Newron Pharmaceuticals and Myung In Pharm have signed a licence agreement to develop, manufacture, and commercialise the former’s glutamate modulator, evenamide, for schizophrenia in South Korea ...

The trial is set to involve a minimum of 600 TRS subjects. Credit: Volha_R / Shutterstock. Newron Pharmaceuticals and Myung In Pharm have signed a licence agreement to develop, manufacture, and ...

MILAN, Italy & MORRISTOWN, New Jersey & SEOUL, Republic of Korea--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a ...

Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In ...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Agreement Newron and Myung In Pharm announce license agreement for evenamide in South Korea 09.01.2025 / 07:00 CET/CEST The issuer is solely ...

Myung In Pharm to develop, manufacture and commercialize evenamide in South Korea Myung In Pharm to contribute 10% of patients to Newron’s pivotal Phase III trial for evenamide, and share global ...